HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

规格	价格/CNY		货期	数量
100 μg	￥ 926	待询
1 mg	￥ 6,227	待询

规格

价格/CNY

货期

数量

100 μg

￥ 926

待询

1 mg

￥ 6,227

待询

产品描述

种属	Human
表达系统	HEK293 Cells
标签	C-His-Avi
蛋白编号	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK
别名	KRAS1, MHC, K-RAS2B, K-RAS4B, NS, GTPase Kras, K-Ras 2, KI-RAS, K-RAS4A, KRAS2, RALD, C-K-RAS, K-RAS2A, RASK2, CFC2, KRAS, NS3
蛋白构建	Gly25-Thr305(HLA-A*11:01),Ile21-Met119(B2M) and VVVGAVGVGK peptide
蛋白纯度	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC

内毒素	< 1 EU/μg by the LAL method.
缓冲液	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
复溶方法	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
存储	Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at-80℃. For reconstituted proteinsolutions, the solution can be stored at -20°c to -80'c for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.